UCB Surges 26% in a Week While Short Sellers Stay on the Sidelines

UCB shares closed at €259.10 on Thursday, up 21.6% on the day and 25.8% over the week, a move that dwarfs the median 3.4% gain among its closest pharma peers ahead of Monday's earnings release.

The most striking feature of that rally is what the lending market is not saying. Short interest in UCB is negligible: availability in the borrow pool amounts to roughly 5,828% of shares already out on loan, meaning there are dozens of shares available for every one currently borrowed. Cost to borrow sits at just 0.70%, and it has barely moved. Nothing in the lending data points to a short squeeze driving this week's gains. The buying is coming from somewhere else.

Ownership tells part of that story. Financière de Tubize, UCB's controlling family vehicle, holds 37% of shares and has not changed its position. Wellington Management filed a fresh stake in the most recent reporting period, adding 5.85 million shares to bring its position from zero. FMR (Fidelity) added nearly 400,000 shares as of August. The week's price move is happening against a backdrop of quiet but steady institutional accumulation, not speculative positioning.

The one data point that may help explain the market's renewed interest in UCB's revenue line comes from the Centers for Medicare and Medicaid Services. Medicaid dollars reimbursed for UCB drugs rose 39% in Q1 2026 compared with Q1 a year earlier, reaching $399 million, and that figure has climbed for four consecutive quarters. The CMS dataset carries no measured lead relationship to UCB's reported figures, so it cannot be read as a pointer to Monday's print. But the trend confirms that demand for the company's reimbursed drug portfolio has been accelerating through the year.

The analyst consensus is a straightforward buy, with 12 firms on that side and no recent rating changes on record. The PE multiple has expanded roughly 3.2 points over the past month to 19.1x, a direct consequence of the share price move rather than any revision to earnings estimates. EPS surprise ranks in only the 23rd percentile historically, meaning UCB does not have a strong track record of beating expectations, a point that gives the valuation expansion added weight going into the release.

Monday's print will test whether the company's revenue growth and margin trajectory justify a share price that has now added more than a quarter of its value in a single week.